Get the Stockscreener App
11.83
1.66%
-0.20
After Hours:
11.83
Generate Biomedicines Inc stock is traded at $11.83, with a volume of 472.86K.
It is down -1.66% in the last 24 hours and up +0.00% over the past month.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
See More
Previous Close:
$12.03
Open:
$12.13
24h Volume:
472.86K
Relative Volume:
2.47
Market Cap:
$1.51B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.17%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.78
$12.85
1-Week Range:
$11.78
$12.85
52-Week Range:
$11.00
$13.95
Generate Biomedicines Inc Stock (GENB) Company Profile
Name
Generate Biomedicines Inc
Sector
Industry
Phone
-
Address
-
Compare GENB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
11.83 | 1.53B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Generate Biomedicines Inc Stock (GENB) Latest News
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - Seeking Alpha
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Piper Sandler - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - marketscreener.com
Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com
Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com Canada
Guggenheim initiates Generate Biomedicines stock with buy rating - Investing.com
Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com UK
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Free cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total debt per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Revenue per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Total liabilities & shareholders' equities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
After tax other income/expense of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
EBIT of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Income Statement – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Dividends – NASDAQ:GENB - TradingView
Net debt of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Tangible book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash from investing activities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Free cash flow of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Cash Flow – NASDAQ:GENB - TradingView
Long term debt to total assets ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total liabilities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBITDA ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to sales ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB News Today | Why did Generate Biomedicines stock go down today? - MarketBeat
Working capital per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Total equity of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Return on assets % of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total assets of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to cash flow ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total common shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (NASDAQ: GENB) holder reports 1.56M-share stake - Stock Titan
GENB SEC FilingsGenerate Biomedicines 10-K, 10-Q, 8-K Forms - Stock Titan
Generate Biomedicines (GENB) Stock Forecast and Price Target 2026 - MarketBeat
Fpn Ii, L.p. Net Worth (2026) - GuruFocus
Generate Biomedicines (GENB) Stock Chart and Price History 2026 - MarketBeat
Goodwin Advises Generate Biomedicines, Inc. On The Closing Of Its $400 Million Initial Public Offering - Mondaq
Generate Biomedicines Inc Stock (GENB) Financials Data
There is no financial data for Generate Biomedicines Inc (GENB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):